Merck/Schering: The Next Wave Of Consolidation
Executive Summary
News of Pfizer's takeover of Wyeth has hardly had time to sink in and already a second mega-merger is shaking up big pharma. This time Merck is the buyer; the company announced March 9 that it proposes to acquire its cardiovascular joint venture partner Schering-Plough in a deal valued at $41.1 billion
You may also be interested in...
Deals Of The Week: Idenix/Janssen, Genentech/Afraxis, Immunomedics/Algeta
With Super Bowl mania rampant, what are the chances of the biopharmaceutical industry’s equivalent: a mega-merger within big pharma? A Wall Street analyst downplays the likelihood of another Pfizer/Wyeth-like pairing, but raises the possibility that industry will see a mid-sized deal intended to mimic the success of the Sanofi/Genzyme merger.
Glycemic Control Not Enough For New Diabetes Drugs, Roche Exec Says
Sponsors must move beyond glycemic control if they want any new therapy for type 2 diabetes to be commercially viable, according to a Roche executive.
Glycemic Control Not Enough For New Diabetes Drugs, Roche Exec Says
Sponsors must move beyond glycemic control if they want any new therapy for type 2 diabetes to be commercially viable, according to a Roche executive.